---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023851"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:42:36.573751+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Erasca Q3 2022 net loss $35.5M; cash $365.5M funds ops into H2 2024

## Summary
- Net loss $35.5M ($0.29/sh) vs $46.1M ($0.46/sh) in Q3 2021; R&D spend $28.2M.
- Cash, cash equivalents & marketable securities $365.5M as of Sep 30, 2022; expects to fund operations into H2 2024.
- Positive preliminary monotherapy data for ERAS-007 and ERAS-601: 23% response in RAS/MAPK-altered non-CRC solid tumors.
- Entered CTCSAs with Lilly (cetuximab + ERAS-601) and Pfizer (palbociclib + ERAS-007); strategic R&D collaboration with MD Anderson.
- Upcoming milestones: IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 by year-end 2022; combo data for ERAS-007/601 in H1 2023.

## SEC filing metadata
- accession: 0000950170-22-023851
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/0000950170-22-023851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/eras-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023851
- JSON: https://secwatch.observer/filing/0000950170-22-023851.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023851.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022.
  - Period: the fiscal quarter ended September 30, 2022
  - Result: reported results
  source text: Erasca, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/0000950170-22-023851-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.